Key Takeaways
- Curaleaf Holdings has publicly disclosed its intention to acquire Aurora Cannabis for US$4.00 per share
- The proposal represents a 45% premium above Aurora’s 30-day volume weighted average price of US$2.75
- Transaction structure includes 0.3463 Curaleaf shares combined with US$0.75 in cash for each Aurora share
- Following the public announcement, Aurora’s stock price climbed 18%, reaching approximately $4.76
- Aurora’s board previously declined engagement following private overtures from Curaleaf on June 23 and July 7, 2026
Following Aurora Cannabis’ board rejection of confidential negotiations, Curaleaf Holdings has taken its acquisition proposal public, announcing an offer valued at US$4.00 per Aurora share.
The Tuesday announcement triggered a significant market reaction, with ACB shares climbing more than 18% during trading to reach $4.76. Even before the opening bell, pre-market activity reflected a 15% increase.
Under the proposed transaction terms, Aurora shareholders would receive 0.3463 subordinate voting shares of Curaleaf along with US$0.75 cash per share held. Using current market valuations, this mix equals the US$4.00 per share offer price.
We intend to acquire Aurora Cannabis. Itās a win-win for all. For $ACB shareholders, the transaction provides a 45% premium over the 30-day VWAP and upside in the strongest global cannabis company. For $CURLF shareholders, the transaction bolsters the supply chain, is immediatelyā¦
ā Curaleaf (@Curaleaf_Inc) August 11, 2026
Compared to Aurora’s 30-day volume weighted average trading price of US$2.75, the proposal delivers a 45% premium. Relative to Monday’s closing price, shareholders would see a 38% gain.
The equity component includes a protective ceiling. Should Curaleaf’s share price increase substantially prior to deal completion, the stock consideration will be adjusted downward to ensure the total package doesn’t surpass US$5.00 per Aurora share, calculated using Curaleaf’s 20-day VWAP.
According to Curaleaf’s disclosure, the company initially contacted Aurora’s management team on June 23, 2026, followed by a second attempt on July 7, 2026. Aurora’s board rejected both overtures without substantive discussions.
Curaleaf CEO Boris Jordan spoke candidly about the rejected negotiations. “We approached Aurora privately and constructively on multiple occasions,” Jordan stated. “We were very disappointed that the Board refused to meaningfully engage.”
Jordan emphasized that Curaleaf would now present the offer directly to Aurora’s shareholder base, characterizing the premium as “compelling” and suggesting that continued resistance would be “unjustified.”
Pro Forma Financial Profile
A merged entity would generate over US$1.5 billion in trailing twelve-month revenue and produce approximately US$350 million in adjusted EBITDA during the same timeframe.
Curaleaf projects the transaction will deliver a minimum of US$40 million in annual operational synergies.
Deal Parameters and Timing
At this stage, no official takeover bid documentation has been submitted. Curaleaf has acknowledged there remains uncertainty whether the proposal will formally proceed.
Curaleaf retains the right to withdraw if its assessment uncovers materially negative information regarding Aurora, if Aurora implements defensive measures, or if Aurora pursues alternative transactions.
Should the bid formally launch, it would stay open for a 105-day period. Notably, the offer would proceed without due diligence contingencies or financing conditions, eliminating two frequent obstacles to deal completion.
Comprehensive offer documentation will be submitted to Canadian securities authorities and the U.S. Securities and Exchange Commission when the formal bid commences.
Canaccord Genuity has been retained as Curaleaf’s financial advisor for the proposed transaction. Dentons provides legal representation.
ACB shares closed at $4.76, representing a gain of $0.73, or 18.11%, for the trading session.





